AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Biofrontera shares rise 12.5% premarket after selling Xepi U.S. license to Pelthos for up to $10M.
ByAinvest
Friday, Nov 7, 2025 8:10 am ET1min read
Biofrontera Inc. (Nasdaq: BFRI) rose 12.5% in premarket trading following the announcement of a $10 million deal to divest its U.S. license for Xepi® (ozenoxacin) Cream to Pelthos Therapeutics. The company received $3 million at closing, with an additional $1 million tied to commercial product availability and up to $6 million in sales milestones linked to revenue thresholds. This transaction strengthens liquidity, supports profitability goals, and funds expansion of its photodynamic therapy (PDT) platform. The upfront cash infusion and potential future payments directly address cash flow concerns, aligning with the stock’s sharp premarket gain. While the company also announced Q3 2025 financial results to be released on November 12, the Xepi deal is the primary catalyst for the price movement.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet